Stocktoria
PUMA BIOTECHNOLOGY, INC. PBYI
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2012-03-21
PUMA BIOTECHNOLOGY, INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $228.4M | $230.5M | $235.6M | $228.0M | $253.2M | $225.1M | $272.3M | $251.0M | $27.7M | — |
| R&D expense | — | — | — | — | $71.9M | $97.7M | $132.9M | $164.9M | $207.8M | $222.8M |
| SG&A expense | $70.8M | $80.2M | $89.9M | $90.0M | $116.3M | $118.5M | $141.6M | $146.2M | $106.7M | $53.8M |
| Operating income | $37.3M | $31.0M | $32.6M | $23.7M | $1.3M | -$30.4M | -$39.0M | -$94.7M | -$292.4M | -$276.6M |
| Interest expense | — | — | $13.3M | $11.6M | $12.8M | $14.0M | $15.0M | $11.0M | $720,000 | — |
| Income tax | $4.7M | -$6.2M | $1.1M | $455,000 | $324,000 | $207,000 | $53,000 | $17,000 | $0 | $0 |
| Net income | $31.1M | $30.3M | $21.6M | $2,000 | -$29.1M | -$60.0M | -$75.6M | -$113.6M | -$292.0M | -$276.0M |
| EPS (diluted) | $0.61 | $0.62 | $0.45 | $0.00 | $-0.72 | $-1.52 | — | — | — | — |
| Operating cash flow | $41.8M | $38.9M | $27.0M | -$15.8M | $20.6M | $773,000 | $22.4M | -$24.1M | -$172.5M | -$141.7M |
| Free cash flow | $41.7M | $38.9M | $26.9M | -$15.8M | $20.6M | $727,000 | $22.1M | -$24.5M | -$172.9M | -$146.0M |
| Cash & equivalents | $29.6M | $69.2M | $84.6M | $76.2M | $63.1M | $85.3M | $60.0M | $108.4M | $81.7M | $194.5M |
| Inventory | $5.5M | $8.7M | $7.1M | $4.5M | $7.1M | $3.5M | $3.2M | $2.6M | $2.0M | — |
| Total assets | $216.3M | $213.3M | $230.5M | $222.1M | $226.6M | $244.2M | $234.9M | $259.1M | $165.5M | $252.8M |
| Total liabilities | $86.0M | $121.2M | $177.1M | $200.5M | $229.0M | $250.2M | $217.4M | $224.8M | $112.2M | $43.0M |
| Shareholders' equity | $130.3M | $92.1M | $53.4M | $21.6M | -$2.4M | -$6.0M | $17.5M | $34.3M | $53.3M | $209.8M |
Growth · year-over-year · Revenue CAGR 30.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -0.9% | -2.2% | +3.3% | -9.9% | +12.5% | -17.3% | +8.5% | +806.6% | — | — |
| Net income growth | +2.8% | +40.2% | +1079450.0% | — | — | — | — | — | — | — |
| EPS growth | -1.6% | +37.8% | — | — | — | — | — | — | — | — |
| Free cash flow growth | +7.4% | +44.6% | — | -176.6% | +2740.4% | -96.7% | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.